December 16, 2013 — BioTelemetry Inc., a wireless medical technology company focused on the delivery of health information, announced that recently published research from an observational study of more than 200,000 patients demonstrates significant in-hospital cost savings in the 12 months following diagnosis using mobile cardiac telemetry (MCT).
A retrospective analysis was completed on claims data spanning 57 months and greater than 200,000 patients to compare diagnostic efficacy, therapeutic outcomes and cardiovascular costs incurred in the hospital setting for patients diagnosed with MCT, Holter and event devices. Results published in Medical Device: Evidence and Research demonstrate a significantly higher diagnostic yield in patients utilizing MCT (61%) compared to event (23%) and Holter (24%). Therapeutic intervention measured through the prescription of antiarrhythmic drugs was also substantially higher in patients monitored with MCT (61%) compared to event (39%) and Holter (43%). The study's most significant finding was the level of cost savings per patient in cardiovascular in-hospital costs when an MCT is used versus either an event or Holter monitor. The study shows that the substitution of the MCT for an event or Holter monitor provides a 10-to-15 times return on investment (ROI) in the first 12 months post-utilization.
"With the shift in healthcare payments from procedure-based to outcomes-based, we are pleased, but not surprised, with the results of this large scale study,” said Joseph Capper, president and CEO, BioTelemetry. “While the diagnostic superiority of our MCOT technology has been demonstrated repeatedly through numerous peer-reviewed studies and abstracts, these prior studies have stopped short of evaluating the actual cost-benefit of MCOT use resulting from the improved efficacy and better outcomes. This data provides evidence that MCOT is a cost beneficial technology that delivers unsurpassed results to physicians while also reducing overall healthcare spending. This is one of the few studies to validate real savings derived from the application of a mobile health platform. We look forward to sharing this newly released data with our healthcare partners."
For more information: www.biotelinc.com, www.dovepress.com